Review Article

You have full text access to this OnlineOpen article

Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?

  1. Hironori Koga M.D.†,*

Article first published online: 25 JUN 2003

DOI: 10.1002/cncr.11576

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 661–667, 15 August 2003

Additional Information

How to Cite

Koga, H. (2003), Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. Cancer, 98: 661–667. doi: 10.1002/cncr.11576

Author Information

  1. Second Department of Medicine, and Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan

  1. †

    Fax: (011) 81-942-34-2623

*Second Department of Medicine, and Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 25 JUN 2003
  3. Manuscript Accepted: 12 MAY 2003
  4. Manuscript Revised: 5 MAY 2003
  5. Manuscript Received: 21 OCT 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (181K)

REFERENCES

  • 1
    London WT. Primary hepatocellular carcinoma: aetiology, pathogenesis, and prevention. Hum Pathol. 1981; 12: 1085–1097.
  • 2
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745–750.
  • 3
    Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997; 350: 1142–1143.
  • 4
    Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998; 351: 214–215.
  • 5
    Okuda K. Hepatocellular carcinoma. J Hepatol. 2000; 32 (Suppl 1): 225–237.
  • 6
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999; 131: 174–181.
  • 7
    El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002; 36: S74–S83.
    Direct Link:
  • 8
    Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998; 28: 1241–1246.
    Direct Link:
  • 9
    Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol. 1990; 5: 616–626.
    Direct Link:
  • 10
    Imari Y, Sakamoto S, Shiomichi S, et al. Hepatocellular carcinoma not detected with plain US: treatment with percutaneous ethanol injection under guidance with enhanced US. Radiology. 1992; 185: 497–500.
  • 11
    Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232: 381–391.
  • 12
    Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987; 163: 345–351.
  • 13
    Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer. 1991; 68: 2150–2154.
    Direct Link:
  • 14
    Leyendecker JR, Dodd GD III. Minimally invasive techniques for the treatment of liver tumors. Semin Liver Dis. 2001; 21: 283–291.
  • 15
    Terada T, Nakanuma Y. Multiple occurrence of borderline hepatocellular nodules in human cirrhotic livers: possible multicentric origin of hepatocellular carcinoma. Virchows Arch. 1995; 427: 379–383.
  • 16
    Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 1999; 29: 1446–1452.
    Direct Link:
  • 17
    Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann Surg. 1999; 229: 84–90.
  • 18
    Eguchi H, Umeshita K, Sakon M, et al. Presence of active hepatitis associated with liver cirrhosis is a risk factor for mortality caused by posthepatectomy liver failure. Dig Dis Sci. 2000; 45: 1383–1388.
  • 19
    Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology. 1990; 37: 188–193.
  • 20
    Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology. 1998; 28: 436–442.
    Direct Link:
  • 21
    Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33: 1394–1403.
    Direct Link:
  • 22
    Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg. 2002; 26: 257–263.
  • 23
    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBX gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991; 351: 317–320.
  • 24
    Yen TSB. Hepadnaviral X protein: review of recent progress. J Biomed Sci. 1996; 3: 20–30.
  • 25
    Wu CG, Forgues M, Siddique S, Farnsworth J, Valerie K, Wang XW. SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J. 2002; 16: 1665–1667.
  • 26
    Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998; 4: 1065–1067.
  • 27
    You LR, Chen CM, Lee YH. Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. J Virol. 1999; 73: 1672–1681.
  • 28
    Kato N, Yoshida H, Kioko Ono-Nita S, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. 2000; 32: 405–412.
    Direct Link:
  • 29
    Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology. 2000; 31: 656–664.
    Direct Link:
  • 30
    Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatic C virus core protein leads to cellular transformation. J Exp Med. 2002; 196: 641–653.
  • 31
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346: 1051–1055.
  • 32
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001; 34: 593–602.
  • 33
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med. 2001; 134: 963–967.
  • 34
    Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003; 138: 299–306.
  • 35
    Muto Y, Mariachi H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996; 334: 1561–1567.
  • 36
    Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999; 340: 1046–1047.
  • 37
    Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res. 1990; 81: 1281–1285.
  • 38
    Nakamura N, Shidoji Y, Moriwaki H, Muto Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem Biophys Res Commun. 1996; 219: 100–104.
  • 39
    Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res. 1997; 3: 727–731.
  • 40
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93: 705–716.
  • 41
    Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun. 2000; 273: 485–491.
  • 42
    Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA. 2001; 98: 6905–6910.
  • 43
    Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001; 121: 1339–1347.
  • 44
    Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nat Med. 2001; 7: 1048–1051.
  • 45
    Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362–366.
  • 46
    Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001; 276: 18563–18569.
  • 47
    Sheng H, Shao J, DuBois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 2001; 61: 2670–2675.
  • 48
    Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002; 35: 552–559.
    Direct Link:
  • 49
    Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein through suppression of matrix metalloproteinase-9 expression. Cancer Res. 2000; 60: 2555–2561.
  • 50
    Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001; 282: 671–677.
  • 51
    Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 2002; 35: 1117–1124.
    Direct Link:
  • 52
    Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996; 56: 4566–4569.
  • 53
    Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997; 99: 2254–2259.
  • 54
    Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998; 58: 409–412.
  • 55
    Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000; 60: 293–297.
  • 56
    Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001; 61: 1733–1740.
  • 57
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342: 1946–1952.
  • 58
    Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999; 29: 688–696.
    Direct Link:
  • 59
    Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology. 1999; 46: 407–412.
  • 60
    Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 4005–4012.
  • 61
    Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. 2000; 60: 2085–2089.
  • 62
    Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res. 2001; 7: 1410–1418.
  • 63
    Cheng J, Imanishi H, Amuro Y, Hada T. NS-398, a selective cyclooxygenase-2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer. 2002; 99: 755–761.
    Direct Link:
  • 64
    Morinaga S, Yamamoto Y, Noguchi Y, et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol. 2002; 17: 1110–1116.
    Direct Link:
  • 65
    Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology. 2002; 36: 885–894.
  • 66
    Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997; 79: 688–694.
    Direct Link:
  • 67
    Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 1999; 86: 589–595.
    Direct Link:
  • 68
    Hino O, Kajino K, Umeda T, Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol. 2002; 37: 883–887.
  • 69
    Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994; 221: 889–897.
    Direct Link:
  • 70
    Sirois J, Levy LO, Simmons DL, Richards JS. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. Identification of functional and protein-binding regions. J Biol Chem. 1993; 268: 12199–12206.
  • 71
    Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992; 267: 4338–4344.
  • 72
    Lim JW, Kim H, Kim KH. Nuclear factor-κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest. 2001; 81: 349–360.
  • 73
    Agoff SN, Brentnall TA, Crispin DA, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000; 157: 737–745.
  • 74
    Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxyganse-2 expression in gastric epithelial cells. Cancer Res. 2001; 61: 2399–2403.
  • 75
    Sung JJ, Leung WK, Go My, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000; 157: 729–735.
  • 76
    Mise M, Arii S, Higashitsuji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996; 23: 455–464.
    Direct Link:
  • 77
    El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27: 1554–1562.
    Direct Link:
  • 78
    Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001; 1: 11–21.
  • 79
    Trifan OC, Smith RM, Thompson BD, Hla T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem. 1999; 274: 34141–34147.
  • 80
    Zahner G, Wolf G, Ayoub M, et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1. J Biol Chem. 2002; 277: 9763–9771.
  • 81
    Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel Lindau tumor suppressor and HIF-1α: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J. 2002; 16: 264–266.
  • 82
    Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit αVβ 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med. 2001; 7: 1041–1047.
  • 83
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997; 272: 3406–3410.
  • 84
    Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol. 2001; 62: 1587–1595.
  • 85
    Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 1994; 79: 1147–1156.
  • 86
    Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998; 4: 1046–1052.
  • 87
    Morrison RF, Farmer SR. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis. J Biol Chem. 1999; 274: 17088–17097.
  • 88
    Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPARγ-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 2002; 98: 817–823.
    Direct Link:
  • 89
    Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002; 302: 18–25.
  • 90
    Wick M, Hurteau G, Dessev C, et al. Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002; 62: 1207–1214.
  • 91
    Koga H, Sakisaka S, Harada M, et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001; 33: 1087–1097.
    Direct Link:
  • 92
    Koga H, Harada M, Kumemura H, et al. Troglitazone induces p27Kip1-associated cell cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology. 2003; 37: 1086–1096.
    Direct Link:
  • 93
    Hu KQ. Rationale and feasibility of chemoprevention of hapatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med. 2002; 139: 234–243.
  • 94
    Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol. 2002; 15: 480–488.
  • 95
    Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med. 2003; 163: 114–115.
  • 96
    Merlani G, Fox M, Oehen HP, et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol. 2001; 57: 321–326.
  • 97
    Alegria P, Lebre L, Chagas C. Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med. 2002; 137: 75.
  • 98
    Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002; 25: 633–648.
  • 99
    Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998; 338: 916–917.
  • 100
    Shishido S, Koga H, Harada M, et al. Hydrogen peroxide overproduction in megamitochondria in troglitazone-treated human hepatocytes. Hepatology. 2003; 37: 136–147.
    Direct Link:
  • 101
    Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut. 2001; 48: 339–346.
  • 102
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347: 2162–2164.
  • 103
    Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 2002; 8: 2442–2447.
  • 104
    Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002; 62: 5778–5784.
  • 105
    Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res. 2000; 6: 2513–2520.
  • 106
    Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res. 2001; 7: 2998–3005.
  • 107
    Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002; 62: 3956–3961.
  • 108
    Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001; 193: 827–838.
  • 109
    Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor γ ligands. J Biol Chem. 2002; 277: 12503–12506.
  • 110
    Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002; 74: 155–165.
View Full Article (HTML) Get PDF (181K)